30.06.2013 Views

How does the operation of PHARMAC's 'Community Exceptional ...

How does the operation of PHARMAC's 'Community Exceptional ...

How does the operation of PHARMAC's 'Community Exceptional ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

supporting <strong>the</strong>m and his wife also has breast cancer. What is <strong>the</strong><br />

difference? There is no difference…<strong>the</strong>re is no difference.<br />

(Interviewee B)<br />

When ‘B’ was asked if PHARMAC always sticks to <strong>the</strong> criteria for Community<br />

<strong>Exceptional</strong> Circumstances when deciding a claim, ‘B’ admitted that on<br />

occasions PHARMAC uses <strong>the</strong> policy as a mechanism for solving a problem.<br />

‘B’ gave <strong>the</strong> example where Community <strong>Exceptional</strong> Circumstances subsidy<br />

was granted to a lot more than 10 patients with <strong>the</strong> same problem. In <strong>the</strong>se<br />

cases, PHARMAC was not sure if <strong>the</strong>re are enough patients to subsidise <strong>the</strong><br />

drug on <strong>the</strong> schedule. Also ‘B’ explained that when <strong>the</strong>re were some patients<br />

where <strong>the</strong> costs <strong>of</strong> treatment are extraordinarily high, and <strong>the</strong>re are a low<br />

number <strong>of</strong> patients, drug companies will not take up a contract because <strong>the</strong><br />

numbers are so low in New Zealand. In <strong>the</strong>se instances, PHARMAC<br />

sometimes used Community <strong>Exceptional</strong> Circumstances subsidy to fund <strong>the</strong><br />

drug.<br />

On occasions, <strong>the</strong> EC scheme is used as a mechanism to fund<br />

something where <strong>the</strong>re is a pressing need but no o<strong>the</strong>r way <strong>of</strong> doing<br />

it. Liothyoronine 54 is an example <strong>of</strong> this. (Interviewee B)<br />

‘B’ stated that PHARMAC used <strong>the</strong> Community <strong>Exceptional</strong> Circumstances<br />

policy more as a cost containing strategy and not strictly a mechanism for<br />

ascertaining if an individual should be funded for a medicine which is outside<br />

<strong>the</strong> pharmaceutical schedule. The criteria were used by <strong>the</strong> Community<br />

<strong>Exceptional</strong> Circumstances Panel to assess each claim. Decisions are based<br />

on <strong>the</strong> panel members’ knowledge <strong>of</strong> <strong>the</strong> medical condition, rarity and <strong>the</strong><br />

evidence <strong>of</strong> cost-effectiveness <strong>of</strong> <strong>the</strong> proposed treatment. Cost containment is<br />

not stated as a criterion. <strong>How</strong>ever, <strong>the</strong> way ‘B’ described <strong>the</strong> management <strong>of</strong><br />

<strong>the</strong> Community <strong>Exceptional</strong> Circumstances, policy; it has been used as an<br />

effective cost containment policy.<br />

54 Liothyoronine is <strong>the</strong> most potent form <strong>of</strong> thyroid hormone which regulates protein, fat, and carbohydrate metabolism.<br />

It acts on <strong>the</strong> body to increase <strong>the</strong> metabolic rate, <strong>the</strong> syn<strong>the</strong>sis <strong>of</strong> proteins and increases <strong>the</strong> body's sensitivity to<br />

adrenaline. See http://en.wikipedia.org/wiki/Liothyronine_sodium<br />

166

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!